Medication info
Lyrica Capsule 150mg (Pregabalin)

Lyrica Capsule 150mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Korea Hyuntex Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a white body and cap containing a white powder that is white or light yellow in color.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201600254 · Approved 2016.01.14 · Insurance code 649102950

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, and treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. Peripheral neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily The total daily dose (mg/day) should be divided as specified in the administration regimen. The supplemental dose refers to an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. No dosage adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Korea Hyuntex Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, and treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct in patients with epilepsy experiencing partial seizures, particularly when these are accompanied by secondary generalization or not. It is helpful in alleviating pain in fibromyalgia patients. This medication is effective for various neurological diseases and pain conditions, and it is used to improve the patient's symptoms.

How to take

Adult dose

Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. Peripheral neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily The total daily dose (mg/day) should be divided as specified in the administration regimen. The supplemental dose refers to an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. No dosage adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so careful monitoring for signs of depression, mood changes, or unusual behavior is necessary during use. Do not take this medication if you have hypersensitivity to any of its components or if you have certain genetic lactose metabolism disorders. Diabetic patients should be cautious as weight gain may require adjustment of diabetes control medications. If severe allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be careful as there is a risk of falling due to dizziness or drowsiness caused by this medication. Temporary blurred vision or changes in vision may occur, and if such symptoms arise, consult a physician. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced as directed by a physician. Patients with a history of substance abuse may have a higher risk of misuse with this medication, so special caution is advised during use. Patients with poor cardiac or renal function should consult with a doctor before taking this medication, as dose adjustments may be necessary. Taking this medication with opioid analgesics can increase the risk of central nervous system depression, so caution is advised. Pregnant women should avoid use during early pregnancy as it may affect the fetus, and women of childbearing age should use effective contraceptive methods. Nursing mothers should consult with a physician about the possibility of this medication passing into breast milk and whether to discontinue nursing or the medication. Before driving or operating hazardous machinery, check if this medication causes drowsiness or dizziness, and avoid such activities if symptoms are present. In case of overdose, symptoms such as drowsiness, confusion, and depression may appear, and blood dialysis may be necessary as needed.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 212 more
  • loss of consciousness
  • confusion
  • psychiatric disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • sexual dysfunction
  • restlessness
  • anxiety
  • mood instability
  • emotional low
  • emotional high
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • fainting
  • stupor
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing disorder
  • blurred vision
  • diplopia
  • peripheral vision loss
  • visual disturbances
  • field defects
  • photophobia
  • dry eyes
  • ocular swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • vibrational changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • breathlessness
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling of intoxication
  • unusual sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased potassium level
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • mucous membrane syndrome
  • erythema multiforme
  • delirium
  • paralysis
  • mood disorders
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • seizures
  • fatigue
  • weakness
  • gait abnormalities
  • sleep disorders
  • ataxia
  • verbal disorder
  • bloody stool
  • increased BUN
  • urination difficulties
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to keep it at room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a white body and cap containing a white powder that is white or light yellow in color.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.